The biggest mistake I see people make is picking a provider based on the flashiest Instagram ad and not checking whether the pharmacy behind the medication is even named anywhere on the site. A lot of telehealth platforms are vague about where your vials come from. That alone should be a dealbreaker.
Below I’ve split twelve solid options by what kind of buyer you are. No single “best overall.” Different situations call for different picks.
For Value-First Cash Payers Who Still Want Accountability
1. Hims & Hers (post-March 2026 pivot)
After settling with Novo Nordisk in March 2026, Hims & Hers stopped selling compounded GLP-1s and moved to branded meds. Injectable Wegovy runs about $299/mo, oral semaglutide around $249, and Zepbound around $399. If you qualify for insurance plus a savings card, the out-of-pocket cost can drop to almost nothing. Big brand, real medications, but cash pricing without insurance is steep.
2. HealthRX
This one earns its spot near the top on pure value. Compounded tirzepatide starts at $149 per month, cash, with free overnight shipping to all fifty states. The physician review turnaround is roughly 24 hours. What I actually checked before recommending it: the dispensing pharmacy is Manifest Pharmacy in Greer, South Carolina, a named 503A/USP-797-compliant facility with lot-tracked vials. The platform carries LegitScript certification (cert 50087439). For a cash-pay patient who wants accountability without a $300-plus price tag, those details matter more than any marketing claim. Compounded medications are not FDA-approved, so keep that in mind going in.
3. Henry Meds
Henry Meds is a cash-pay compounding option with first-month pricing in the $179 to $249 range and a reputation for fast shipping, sometimes 24 to 72 hours. The monitoring is lighter than some competitors, which cuts cost but also means you carry more of the responsibility for tracking your own response.
4. MEDVi
First month around $179, no contracts, compounded. It does not get much attention compared to the bigger brands but it fills the same practical gap as Henry Meds. Worth a quote if you want to compare cash pricing directly.
For People Who Want Published Lab Data or a Broader Catalog
5. FormBlends
FormBlends is a compounded GLP-1 telehealth option with physician oversight, and it distinguishes itself in one specific way that most competitors do not: it publishes per-product purity testing with actual numbers, including HPLC purity percentages, mass spectrometry identity confirmation, and endotoxin/sterility results. For a buyer who wants to see documented proof of what is in the vial before injecting it, that matters. Cash pricing for tirzepatide runs around $349 per vial, higher than HealthRX’s entry price. Shipping covers 47 states, not all 50. It also carries a broader peptide catalog covering recovery, longevity, and cognitive support under the same clinician model, which is rare in the GLP-1-only telehealth space. My honest take: if price is your primary filter, HealthRX wins. If you want published lab documentation or you are already interested in peptide therapy beyond GLP-1s and want one provider for both, FormBlends earns serious consideration.
For Monitored, Clinician-Heavy Programs
6. Mochi Health
Board-certified obesity medicine clinicians run the show here. Compounded tirzepatide around $199 per month, semaglutide around $99. More active monitoring than most budget options. Good middle ground between bare-bones telehealth and a full coaching program.
7. Form Health
Premium tier. About $299 per month, and that includes labs and meals with both an MD and a registered dietitian assigned to you. Not for cost-sensitive buyers. For people who have tried cheaper programs and stalled, this level of oversight sometimes actually moves the needle.
8. Calibrate
Twelve-month structured program with coaching, fees for the program and medications billed separately. Higher total commitment. Best fit for someone who wants the full behavior-change framework, not just a prescription.
For Insurance Users and Branded Medication Seekers
9. Ro / Ro Body
Membership starts around $39 for the first month, then $74 to $149 monthly, with medications billed separately. Ro has a prior-authorization team that works insurance for branded meds, which is worth something if you have coverage that might actually pay.
10. PlushCare
Monthly membership around $19.99 with same-day visit availability and insurance acceptance for branded medications. Straightforward. Good choice if your insurance plan covers Wegovy or Zepbound and you just need a fast clinical visit.
For Flexible or Budget-Adjacent Approaches
11. Sesame
Annual membership from about $59 per month, medications priced separately. Sesame operates more like a marketplace connecting patients to providers. Less hand-holding, more price transparency. Worth a look if you want to keep the prescription and pharmacy decisions modular.
12. Found
Platform fee around $99 per month plus meds, with coaching built in. Not the cheapest, not the most medically intensive. Sits in the middle and works for people who want structured check-ins without committing to a year-long program.
A Quick Note on the 2026 Regulatory Shift
The FDA sent warning letters to more than thirty telehealth and compounding firms in early 2026. That shook up the market. Some brands exited compounded GLP-1s entirely. Others stayed in by tightening pharmacy partnerships. When comparing options, ask specifically which pharmacy fulfills the order and whether it is 503A or 503B compliant. Vague answers are a red flag.
Lilly also launched oral orforglipron through LillyDirect around April 2026 at roughly $149 per month, which gives cash-pay patients a branded oral option that did not exist a year ago.
Common Questions
What is the practical difference between a 503A and 503B compounding pharmacy for tirzepatide?
503A pharmacies fill patient-specific prescriptions and operate under state pharmacy board oversight. 503B outsourcing facilities produce larger batches under FDA manufacturing standards closer to those applied to branded drugs. Either can be legitimate, but 503B facilities face more federal scrutiny, which some buyers treat as an added quality signal. Ask your provider which designation their pharmacy holds before ordering.
Why does HealthRX cost so much less than FormBlends for what looks like the same compounded tirzepatide?
Pricing differences between compounding telehealth platforms usually come down to pharmacy overhead, testing commitments, and margin structure. FormBlends publishes HPLC purity percentages and mass spectrometry results per batch, which adds real cost. HealthRX keeps overhead lower and passes that to the patient. Neither is inherently unsafe, but the tradeoff between price and documented lab transparency is real and worth deciding consciously.
After Hims & Hers stopped selling compounded GLP-1s in March 2026, where did those patients actually go?
No single platform absorbed them. Many moved to cash-pay compounding options like HealthRX, Henry Meds, or Mochi Health. Some qualified for Zepbound through insurance and shifted to PlushCare or Ro for the prior-authorization support. The exit from compounded GLP-1s by a major brand pushed more buyers to ask harder questions about pharmacy sourcing, which is arguably a useful side effect.
If my insurance might cover Zepbound, which of these platforms is actually worth using to chase that coverage?
Ro and PlushCare are the clearest fits here. Ro has a dedicated prior-authorization team built for this exact situation. PlushCare accepts insurance directly and offers same-day visits, so you can get the clinical documentation your insurer needs without a long wait. If your plan covers Zepbound, either platform can run the paperwork faster than most primary care offices will.
Does FormBlends ship to all fifty states, and does that matter if I live somewhere with stricter compounding rules?
FormBlends currently ships to 47 states, not all 50. The three excluded states have their own compounding pharmacy regulations that create shipping restrictions. If you live in one of those states, HealthRX’s fifty-state coverage is a concrete advantage. State-level compounding rules change periodically, so it is worth confirming your state’s status directly with any platform before you pay for a first month.
Sources
- FDA warning letters to compounding firms and telehealth providers, 2026 (FDA.gov announcements)
- SURMOUNT-1 trial: tirzepatide efficacy at 72 weeks, published in *The New England Journal of Medicine*, 2022
- STEP 1 trial: semaglutide efficacy at 68 weeks, published in *The New England Journal of Medicine*, 2021
- Novo Nordisk / Hims & Hers settlement reporting, March 2026 (Reuters, STAT News)
- LillyDirect orforglipron launch pricing, April 2026 (Eli Lilly press release and news coverage)
- LegitScript certification database (LegitScript.com)
